我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
122
84 进行中
药物批准
3
批准总数
监管机构
1
监管机构数
成立时间
1976
进行中（未招募）
79
64.8%
已完成
26
21.3%
尚未招募
5
4.1%
招募中
2.5%
终止
6
4.9%
撤回
2
1.6%
NMPA
National Medical Products Administration
- The Delhi High Court rejected Zydus Healthcare's challenge to Helsinn Healthcare's patent for nausea and vomiting medication, ruling that no procedural violations occurred during the patent grant process. - Justice Tejas Karia clarified that pre-grant opposition proceedings and patent examination are distinct processes, with opponents having no right to additional hearings during the examination stage. - The court dismissed the petition on territorial jurisdiction grounds, stating that challenges to Patent Office orders must be filed in the High Court where the relevant Patent Office is located. - Helsinn's patent covers "Compositions and Methods for Treating Centrally Mediated Nausea and Vomiting" and was granted by the Mumbai Patent Office in March 2023 after rejecting Zydus' opposition.
